Profund Advisors LLC raised its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) by 605.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 109,547 shares of the company’s stock after purchasing an additional 94,021 shares during the quarter. Profund Advisors LLC owned 0.18% of Zevra Therapeutics worth $1,202,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the business. AIGH Capital Management LLC acquired a new position in shares of Zevra Therapeutics in the 1st quarter valued at approximately $11,184,000. Hennion & Walsh Asset Management Inc. increased its stake in shares of Zevra Therapeutics by 116.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after buying an additional 206,543 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after buying an additional 400,336 shares during the last quarter. Mystic Asset Management Inc. increased its stake in shares of Zevra Therapeutics by 0.9% in the third quarter. Mystic Asset Management Inc. now owns 355,380 shares of the company’s stock worth $3,899,000 after buying an additional 3,270 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Zevra Therapeutics in the second quarter valued at $2,846,000. Institutional investors and hedge funds own 35.03% of the company’s stock.
Zevra Therapeutics Price Performance
Shares of ZVRA stock opened at $10.10 on Tuesday. Zevra Therapeutics, Inc. has a 12-month low of $8.01 and a 12-month high of $15.03. The firm has a market capitalization of $599.78 million, a price-to-earnings ratio of 10.98 and a beta of 0.98. The business has a 50 day simple moving average of $11.14 and a 200 day simple moving average of $10.74.
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. The firm had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. On average, equities analysts anticipate that Zevra Therapeutics, Inc. will post 0.72 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have commented on ZVRA. Guggenheim reduced their price objective on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. BTIG Research dropped their target price on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Monday, July 27th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Citizens Jmp upped their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, August 6th. Finally, UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $27.14.
Check Out Our Latest Report on Zevra Therapeutics
Insiders Place Their Bets
In related news, Director Corey Watton sold 12,300 shares of Zevra Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the sale, the director directly owned 1,800 shares in the company, valued at $20,250. The trade was a 87.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Neil McFarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the sale, the chief executive officer owned 417,225 shares in the company, valued at approximately $4,693,781.25. This represents a 4.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is currently owned by company insiders.
Zevra Therapeutics Profile
Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.
Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.
Featured Articles
- Five stocks we like better than Zevra Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
